• Sales of $3 million in Q3 FY2026 reflecting seasonal respiratory testing
• Strong balance sheet with $25.7 million in cash and term deposits
• Implemented organizational restructuring to improve operational efficiency, estimated $5 million annual cost savings from FY2027

Genetic Signatures Ltd reported sales of $3 million (unaudited) for Q3 FY2026, reflecting seasonal respiratory testing rates in Australia. The company held a total cash balance of $25.7 million as of 31 March 2026, comprising $17.7 million in cash at bank and $8.0 million in term deposits. Following a comprehensive strategic review, the company has implemented a significant organizational restructuring, resulting in 30 positions being made redundant across five divisions. Concurrently, three new positions have been created focusing on project management and outsourcing capabilities. This restructuring is expected to result in estimated cost savings of $5 million on an annualized basis from FY2027 onwards. The company also commenced transitioning elements of its product development to specialist contract research organizations, while maintaining core intellectual property and technical capabilities in-house. In April 2026, the company signed a ten-year term agreement (extendable by two twelve-month periods) with Hvidovre Hospital in Denmark for the supply of equipment and reagents for the testing of 28,000 clinical samples in year one with an estimated 3% annual growth.

The company is operating in a highly competitive environment, and the unknown severity of the Australian flu season are factors which could have an impact on Q4 FY2026 revenues. Despite this, the company remains focused on delivering new opportunities across the sales pipeline and is well positioned to pursue its objective of scaling into new market opportunities.